Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 2

Infliximab in the treatment of Crohn’s disease

Authors Gilberto Poggioli, Silvio Laureti, Massimo Campieri, Filippo Pierangeli, Paolo Gionchetti, et al

Published 15 May 2007 Volume 2007:3(2) Pages 301—308

Gilberto Poggioli, Silvio Laureti, Massimo Campieri*, Filippo Pierangeli, Paolo Gionchetti*, Federica Ugolini, Lorenzo Gentilini, Piero Bazzi, Fernando Rizzello*, Maurizio Coscia

General Surgery Department; Policlinico S. Orsola; University of Bologna, Italy; *Internal Medicine Department; Policlinico S. Orsola; University of Bologna, Italy

Abstract: The recent introduction of infliximab, a chimeric monoclonal antibody against tumor necrosis factor-α, has greatly modified the treatment of Crohn’s disease (CD). Data from the literature show encouraging results after intravenous infusion both for closure of intestinal or perianal fistulas and for induction and maintenance of remission in patients with moderate to severe intestinal disease unresponsive to other treatments. However, some contraindications such as fibrostenosing CD and sepsis have been identified. In addition, the data on long-term outcomes and safety is still limited. Our initial experience showed that in selected cases local injection of infliximab is effective in the treatment of complex perianal disease offering the possibility of using such treatment even in small bowel obstructing disease with minimal systemic effects. This paper analyzes the state of the use of both intravenous and local injection of infliximab in patients with CD.

Keywords: infliximab, Crohn’s disease, perianal fistulas, local injection

Download Article [PDF] 

Readers of this article also read:

CdTe quantum dots induce activation of human platelets: implications for nanoparticle hemocompatibility

Samuel SP, Santos-Martinez MJ, Medina C, Jain N, Radomski MW, Prina-Mello A, Volkov Y

International Journal of Nanomedicine 2015, 10:2723-2734

Published Date: 2 April 2015

Autoantibody profiling in systemic lupus erythematosus

Hsieh SC, Yu CL

Current Biomarker Findings 2013, 3:55-65

Published Date: 23 August 2013

Pars plana vitrectomy for primary rhegmatogenous retinal detachment

Stephen G Schwartz, Harry W Flynn Jr

Clinical Ophthalmology 2008, 2:57-63

Published Date: 7 March 2008

Association between homocysteinemia and metabolic syndrome in patients with cardiovascular disease

Chiara Bellia, Giulia Bivona, Concetta Scazzone, Marcello Ciaccio

Therapeutics and Clinical Risk Management 2007, 3:999-1001

Published Date: 15 January 2008

Photodynamic diagnosis for follow-up of carcinoma in situ of the bladder

Renzo Colombo, Richard Naspro, Piera Bellinzoni, Fabio Fabbri, Giorgio Guazzoni, et al

Therapeutics and Clinical Risk Management 2007, 3:1003-1007

Published Date: 15 January 2008

Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study

Anja Vogt, Ursula Kassner, Ulrike Hostalek, Elisabeth Steinhagen-Thiessen

Vascular Health and Risk Management 2007, 3:467-479

Published Date: 15 September 2007

Zanamivir for the prevention of influenza in adults and children age 5 years and older

Lea S Eiland, Edward H Eiland

Therapeutics and Clinical Risk Management 2007, 3:461-465

Published Date: 15 July 2007

Conceptualization of depression in Parkinson’s disease

Jeffrey CL Looi, May Matias, Michelle J Ruzich

Neuropsychiatric Disease and Treatment 2005, 1:135-143

Published Date: 15 July 2005